Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)

• Research type

  Research Study

• Full title

  A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM)

• IRAS ID

  18934

• Contact name

  James Larkin

• Sponsor organisation

  The Royal Marsden NHS Trust

• Eudract number

  2009-012945-49

• ISRCTN Number

  39058880

• Research summary

  The aim of this study is to see a drug called nilotinib (Tasigna©) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called c-KIT. Nilotinib interferes with signalling inside cells with this mutation and we believe that this may lead to shrinkage of tumours. Acral melanomas are found on the palms and soles and mucosal melanomas start inside body cavities rather than on the skin. Tumour samples will be tested for the c-KIT mutation and the study will be offered to patients with advanced acral or mucosal melanoma if the mutation is present.

• REC name

  South Central - Oxford C Research Ethics Committee

• REC reference

  09/H0606/103

• Date of REC Opinion

  20 Nov 2009

• REC opinion

  Further Information Favourable Opinion